SHIFT
2010
Systolic Heart failure treatment with the If inhibitor ivabradine Trial
In 6,558 patients with HFrEF (EF ≤ 35%) in sinus rhythm with heart rate ≥ 70 bpm, ivabradine reduced cardiovascular death or hospitalisation for worsening heart failure compared with placebo.
Result
Efficacy: Composite of cardiovascular death or hospitalisation for worsening heart failureHR 0.82 (95% CI 0.75-0.90) · P < 0.0001
Below 1 favours ivabradine, above 1 favours placebo.
- Absolute difference
- 5 points
- NNT
- 20
Absolute difference and NNT are derived from the event rates.
Also reported: Driven mainly by fewer HF hospitalisations.
- Subtopic
- If-channel inhibitor
- Design
- Double-blind placebo-controlled RCT
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2021 HFAHA/ACC 2022 HF
- Source
- Swedberg K, et al. Lancet. 2010;376(9744):875-885.doi 10.1016/S0140-6736(10)61198-1
Discussion & critique
Benefit confined to sinus rhythm with heart rate ≥70 bpm, and background beta-blocker doses often submaximal. Established ivabradine for HFrEF with elevated heart rate despite maximally tolerated beta-blockade.